Inhibition effect of triptolide on human epithelial ovarian cancer via adjusting cellular immunity and angiogenesis

Hu, Hui; Huang, Genhua; Wang, Haibin; Li, Xiaoli; Wang, Xiaobing; Feng, Yali; Tan, Buzhen; Chen, Tingtao

doi:10.3892/or.2017.6158

Cited by 23 publications

(25 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, immunology has been frequently validated to be associated with cancer. The combined use of triptolide and cisplatin enhances the plasma levels of IL-2 and TNF-α in ovarian cancer SKOV3/DDP xenograft mice, which can promote the differentiation of T cells and inhibit tumorigenesis respectively, thus resulting in an inflammatory microenvironment and leading to cancer cell death [446].…”

Section: Triptolidementioning

confidence: 99%

Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine

et al. 2019

View full text Add to dashboard Cite

Numerous natural products originated from Chinese herbal medicine exhibit anti-cancer activities, including antiproliferative, pro-apoptotic, anti-metastatic, anti-angiogenic effects, as well as regulate autophagy, reverse multidrug resistance, balance immunity, and enhance chemotherapy in vitro and in vivo. To provide new insights into the critical path ahead, we systemically reviewed the most recent advances (reported since 2011) on the key compounds with anti-cancer effects derived from Chinese herbal medicine (curcumin, epigallocatechin gallate, berberine, artemisinin, ginsenoside Rg3, ursolic acid, silibinin, emodin, triptolide, cucurbitacin B, tanshinone I, oridonin, shikonin, gambogic acid, artesunate, wogonin, β-elemene, and cepharanthine) in scientific databases (PubMed, Web of Science, Medline, Scopus, and Clinical Trials). With a broader perspective, we focused on their recently discovered and/or investigated pharmacological effects, novel mechanism of action, relevant clinical studies, and their innovative applications in combined therapy and immunomodulation. In addition, the present review has extended to describe other promising compounds including dihydroartemisinin, ginsenoside Rh2, compound K, cucurbitacins D, E, I, tanshinone IIA and cryptotanshinone in view of their potentials in cancer therapy. Up to now, the evidence about the immunomodulatory effects and clinical trials of natural anti-cancer compounds from Chinese herbal medicine is very limited, and further research is needed to monitor their immunoregulatory effects and explore their mechanisms of action as modulators of immune checkpoints.

show abstract

Section: Triptolidementioning

confidence: 99%

Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Also, a proper patient selection based on firmly defined eligibility criteria is needed in order to reduce the degree of toxicity after combined antiangiogenic therapy. Advanced stages of ovarian carcinomas are known to be followed by chemotherapy resistance [21] depending on the cancer associated genetic abnormalities and biological behavior. Besides VEGF, other growth factor molecules are implicated either in promoting or inhibiting tumor angiogenesis in ovarian cancers.…”

Section: Resultsmentioning

confidence: 99%

Clinical and Histopathological Parameters Correlate with Microvessel Density but Not with Vascular Endothelial Growth Factor Expression in Ovarian Cancer

Pirtea¹,

Grigoraș²,

Secoşan³

et al. 2018

Rev. Chim.

View full text Add to dashboard Cite

Ovarian cancer malignancies have the worst prognosis among all gynecological malignancies. As angiogenesis represents a key step for tumor progression, vascular endothelial growth factor (VEGF) is one of the most discussed pro-angiogenic factors. VEGF expression was investigated in 62 cases of ovarian carcinomas. Microvessel density (MVD) was evaluated by correlating the results with clinical and histopathological parameters. Because of the controversial results reported in other studies, VEGF was assessed together with MVD. Our results suggest a more complex angiogenic mechanism in ovarian cancer based on the discrepancies between VEGF expression, microvessel density and their correlation with clinical parameters. The conflicting data arising from this study supports the implications of different growth factors, others than VEGF in ovarian cancer. This hypothesis is sustained by the lack of correlation between VEGF and clinical parameters, and by the significant correlation between microvessel density and clinicopathological parameters. Thus, further studies are needed for a complete evaluation of angiogenesis in ovarian cancer.

show abstract

“…On the other hand, the vasculogenic potential of LCSCs was verified in vivo . An endothelial progenitor marker CD144 ( Wang R. et al, 2010 ), activated the expression of tumor endothelial cell marker CD105, and the pan-endothelial marker CD31 ( Hu et al, 2018 ) was used in combination to highlight the endothelial-like phenotype of LCSCs. Correspondingly, we selected the human-specific CD31 marker for the complete identification of vascular endothelial cells originating from human LCSCs, including active immature and stable mature cells in xenografts.…”

Section: Discussionmentioning

confidence: 99%

Oct4 Regulates the Transition of Cancer Stem-Like Cells to Tumor Endothelial-Like Cells in Human Liver Cancer

Liu

Tang

Yang

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Octamer-binding transcription factor 4 (Oct4) has been recently implicated as a proangiogenic regulator in several induced pluripotent stem cells (iPSCs), however, its role in cancer stem-like cells (CSCs) remain unclear. We report here that Oct4 participates in tumor vasculogenesis in liver CSCs (LCSCs). We identify that LCSCs possess the potential of endothelial trans-differentiation under endothelial induction, present endothelial specific markers and their functions in vitro, and participate in neovasculogenesis in vivo. The knockdown of the Oct4A by short hairpin RNA (shRNA) in LCSCs represses endothelial trans-differentiation potential, but induces endothelial lineage-restricted differentiation, the latter is positively regulated by Oct4B1. Furthermore, Oct4 regulates vasculogenesis in LCSCs may be via the AKT-NF-κB-p65 signaling pathway. This work reveals Oct4, which is a crucial regulator, plays a critical role in tumor endothelial-like cells transition of LCSCs through Oct4A and Oct4B1 by different ways. The simultaneous inhibition of both the isoforms of Oct4 is hence expected to help regress neovascularization derived from CSCs. Our findings may provide insights to the possible new mechanisms of tumor vasculogenesis for primary liver cancer.

show abstract

Inhibition effect of triptolide on human epithelial ovarian cancer via adjusting cellular immunity and angiogenesis

Cited by 23 publications

References 34 publications

Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine

Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine

Clinical and Histopathological Parameters Correlate with Microvessel Density but Not with Vascular Endothelial Growth Factor Expression in Ovarian Cancer

Oct4 Regulates the Transition of Cancer Stem-Like Cells to Tumor Endothelial-Like Cells in Human Liver Cancer

Contact Info

Product

Resources

About